PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD

Key Points

• PensionDanmark increased its Gilead Sciences stake by 12.3% in the second quarter, acquiring 25,515 shares and bringing its holdings to 233,799 shares valued at approximately $29.5 million.
• Gilead reported quarterly revenue of $7.8 billion, exceeding expectations, with product sales excluding Veklury up 10% year over year. However, the company posted a $6.75 per-share loss due largely to acquisition-related costs and higher research spending.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and average price target of $158.04. Gilead also declared a quarterly dividend of $0.82 per share, while declining Veklury sales and a discontinued Trodelvy-Keytruda trial remain key risks.

PensionDanmark Pensionsforsikringsaktieselskab increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 233,799 shares of the biopharmaceutical company's stock after acquiring an additional 25,515 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab's holdings in Gilead Sciences were worth $29,538,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Paulson Wealth Management Inc. boosted its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock valued at $477,000 after buying an additional 67 shares during the last quarter. Essex Financial Services Inc. boosted its holdings in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company's stock valued at $948,000 after acquiring an additional 71 shares during the last quarter. Davidson Trust Co. boosted its holdings in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock valued at $262,000 after acquiring an additional 74 shares during the last quarter. Alpha Cubed Investments LLC grew its stake in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock worth $812,000 after acquiring an additional 75 shares during the period. Finally, Personal CFO Solutions LLC grew its stake in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock worth $561,000 after acquiring an additional 76 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GILD shares. Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Weiss Ratings downgraded shares of Gilead Sciences from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, May 28th. Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday. Morgan Stanley lowered their price target on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Monday, July 27th. Finally, Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $158.04.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 15,000 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company's stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company's stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock worth $10,641,790 in the last three months. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Stock Performance

GILD opened at $130.86 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a market cap of $162.47 billion, a price-to-earnings ratio of -49.01 and a beta of 0.32. The company's 50 day moving average is $129.43 and its 200 day moving average is $136.22. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. During the same period in the prior year, the company earned $2.01 earnings per share. The firm's revenue was up 10.6% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.65 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences's payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source